- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03225066
Efficacy and Safety of Poly-L-lactic Acid (Sculptra)
A Prospective, Randomized, Multicenter, Self-controlled, Blinded Trial on the Efficacy and Safety of Poly-L-lactic Acid - SCULPTRA - for the Treatment of Corporal Skin Flaccidity.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Ethical and General considerations regarding the study conduction: This study protocol will be reviewed and approved by appropriate IEC/IRB prior to the initiation of the study.
Clinical monitoring: Study conduction will be closely monitored by Galderma representatives, following GCP regulations, applicable standard operating procedures, guides and local regulations.
Data Management: Data may be audited by Galderma Quality Assurance Department and/or CRO prior to or after results of the first statistical analysis on the primary discretion.
Quality assurance, auditing and Inspection: The study will be carried out under the sponsorship of Galderma in accordance with all local and federal regulations, as well as ICH guidelines. Audits and inspections at the research site may be conducted by Galderma representatives or local authorities. All aspects in any study step can be audited by Galderma Quality Assurance / CRO and, as a result, a certificate stating this will be provided.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
São Paulo, Brazil, 04022-000
- Universidade Federal de São Paulo - UNIFESP - UNICCO
-
-
RS
-
Porto Alegre, RS, Brazil, 90550141
- Centro Brasileiro de Estudos em Dermatologia
-
-
SP
-
São Paulo, SP, Brazil, 09041-410
- Fundacao do ABC
-
São Paulo, SP, Brazil
- Hospital Israelita Albert Einstin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female;
- Age between 35 and 60 years (including 60 years);
- Indication for treatment of bilateral skin flaccidity of at least one of two corporal areas candidate for treatment (arms [anteromedial region] or gluteal regions);
- Mild to moderate flaccidity in the area to be treated, according to investigator's assessment and in accordance with appropriated flaccidity scales for corporal region to be treated;
- Subjects who understood and signed the Informed Consent Form (ICF) when entering the study, before performing any investigational procedure
Exclusion Criteria:
- Prior use (<1 year) or planning to use any other aesthetic treatment in the corporal area of interest for study, such as radiofrequency, cryolipolysis;
- History of liposuction, plastic surgery and / or corrective plastic surgery in the area of the body of interest for the study (arms or gluteal region);
- History (<1year) of treatment with Sculptra in other corporal area, area without interest for study;
- History of Sculptra treatment in the area of the body of interest for the study (arms or gluteal region);
- Any type of comorbidity or clinical condition that, at investigator s discretion, could interfere with study assessments;
- Using or planning to initiate restrictive diets (at investigator s discretion);
- Using or planning to initiate use of supplements for weight loss;
- Diabetes mellitus type 1 or type 2;
- Autoimmune diseases, collagenosis, decompensated endocrine diseases or any disease that, at investigator's discretion, could interfere with study assessments;
- Using or have used within 3 months drugs such as corticosteroids, immunosuppressants or others collagen-production inhibitors;
- Initiated use of hormones or change in dose of hormonal replacement therapy within 3 months;
- Practices regularly or intend to practice during the study high-performance or impact physical activities, such as weight lifting, marathon, triathlon;
- Pregnant or breastfeeding, or wishes to get pregnant within the next 18 months, or refuses to use appropriate contraceptive method (in case of women of childbearing potential).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Poly-L-Lactic Acid - Sculptra
Each area will be treated with a dose contained in a vial of Sculptra®.
For conducting the study, six vials of the product will be available per subject, and one vial will be used in each session with up to maximum a total volume of 16mL per treated area.
It will be 3 session with interval of 1 month in total.
|
Participants using Sculptra - Poly-L-lactic acid 3 sessions in the first side and 3 sessions on the second side
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess the aesthetic effect through photographs via GAIS score determined by blind evaluator
Time Frame: 4 months after starting Side 1 treatment
|
To see the percentage of research subjects, to which the blind evaluator assigned a Global Aesthetic Improvement Scale score (GAIS) score higher to Side 1 than the corporal side which will be the second to receive treatment (Side 2), 4 months after starting Side 1 treatment.
|
4 months after starting Side 1 treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess the frequency with which the blind evaluators identified correctly Side 1, 4 months after initiating treatment on Side 1 through photographs.
Time Frame: 4 months after starting Side 1 treatment
|
1. Percentage of evaluators identifying correctly the first treated side, 4 months after initiating treatment on Side 1.
|
4 months after starting Side 1 treatment
|
Assess efficacy of Sculptra in the treatment of skin flaccidity via GAIS score determined by the investigator.
Time Frame: 4, 6 and 12 months after starting side 1 treatment and 6 and 8 months after starting side 2
|
3.1. Mean GAIS score assigned by the investigator to Side 1, 4 months after initiating treatment. 3.2. Mean GAIS score assigned by the investigator to Side 1, 6 months after initiating treatment. 3.3. Mean GAIS score assigned by the investigator to Side 1, 12 months after initiating treatment. 3.4. Mean GAIS score assigned by the investigator to Side 2, 6 months after initiating treatment. 3.5. Mean GAIS score assigned by the investigator to Side 2, 8 months after initiating treatment. |
4, 6 and 12 months after starting side 1 treatment and 6 and 8 months after starting side 2
|
To assess the aesthetic effect of Sculptra in the skin flaccidity treatment, treatment, via GAIS score determined by the research subject.
Time Frame: 4, 6 and 12 months after initiating side 1 as well as 6 and 8 months after initiating side 2 treatment
|
4.1. Mean GAIS score assigned by the research subject to Side1, 4 months after initiating treatment. 4.2. Mean GAIS score assigned by the female subject to Side1, 6 months after initiating treatment. 4.3. Mean GAIS score assigned by the female subject to Side1, 12 months after initiating treatment. 4.4. Mean GAIS score assigned by the female subject to Side2, 6 months after initiating treatment. 4.5. Mean GAIS score assigned by the female subject to Side2, 8 months after initiating treatment. |
4, 6 and 12 months after initiating side 1 as well as 6 and 8 months after initiating side 2 treatment
|
To assess aesthetic effect of Sculptra on skin flaccidity via GAIS score determined by the investigator
Time Frame: 4 months after initiating side 1 treatment
|
Percentage of research subjects to which the investigator assigned a GAIS score to Side 1, 4 months after initiating treatment, indicating aesthetic improvement (GAIS score between 3 and 5) in relation to pre-treatment condition.
|
4 months after initiating side 1 treatment
|
Evaluate aesthetic effect of Sculptra on skin flaccidity by comparing Side1 to Side2 by the investigator.
Time Frame: 4 months after initiating Side 1 treatment
|
Percentage of research subjects to which the investigator determined that the treated side (Side1) is aesthetically better than the non-treated side, 4 months after initiating Side1 treatment.
|
4 months after initiating Side 1 treatment
|
Assess the aesthetic effect of Sculptra on skin flaccidity, by comparing S1 to S2 by the research subject.
Time Frame: 4 months after initiating side 1 treatment
|
Percentage of research subjects evaluating the treated side (Side1) as aesthetically better than the non-treated side (Side2), 4 months after initiating Side1 treatment.
|
4 months after initiating side 1 treatment
|
Assess the effect of Sculptra on dermal thickness, via high-frequency ultrasound.
Time Frame: 4, 6 and 12 months after initiating side 1 treatment as well as 2 and 8 months after initiating Side 2 treatment
|
8.1. Variation of Side1 dermal thickness between baseline visit and 4 months after initiating treatment. 8.2. Variation of Side1 dermal thickness between baseline visit and 6 months after initiating treatment. 8.3. Variation of Side1 dermal thickness between baseline visit and 12 months after initiating treatment. 8.4. Variation of Side2 dermal thickness between baseline visit and 2 months after initiating treatment. 8.5. Variation of Side2 dermal thickness between baseline visit and 8 months after initiating treatment. |
4, 6 and 12 months after initiating side 1 treatment as well as 2 and 8 months after initiating Side 2 treatment
|
Assess the subject s discomfort with Sculptra application.
Time Frame: 1 year
|
Mean score of subject s discomfort with Sculptra application during treatment period.
|
1 year
|
Evaluate Sculptra effect on arm circumference, 4, and 12 months after initiating Side 1 treatment
Time Frame: 4 and 12 months after initiating side 1 treatment
|
10.1. Variation of Side1 arm circumference between baseline visit and 4 months after initiating treatment. 10.2. Variation of Side1 arm circumference between baseline visit and 12 months after initiating treatment. |
4 and 12 months after initiating side 1 treatment
|
Assess investigator s satisfaction and perception of aesthetic result obtained with Sculptra.
Time Frame: 4, 6 and 12 months after initiating side 1 treatment as well as 6 and 8 months after initiating side 2 treatment
|
11.1.Descriptive statistics of the satisfaction questionnaire and aesthetic result perception, completed by the investigator 4 months after initiating Side1 treatment. 11.2. Descriptive statistics of the satisfaction questionnaire and aesthetic result perception, completed by the investigator 6 months after initiating Side1 treatment. 11.3. Descriptive statistics of the satisfaction questionnaire and aesthetic result perception, completed by the investigator 12 months after initiating Side1 treatment. 11.4. Descriptive statistics of the satisfaction questionnaire and aesthetic result perception, completed by the investigator 6 months after initiating Side2 treatment. 11.5. Descriptive statistics of the satisfaction questionnaire and aesthetic result perception, completed by the investigator 8 months after initiating Side2 treatment. |
4, 6 and 12 months after initiating side 1 treatment as well as 6 and 8 months after initiating side 2 treatment
|
Assess subject s satisfaction and aesthetic result perception obtained with Sculptra
Time Frame: 4, 6 and 12 months after initiating Side 1 treatment, as well as 6 and 8 months after initiating Side2 treatment
|
12.1. Descriptive statistics of satisfaction questionnaire and aesthetic result perception, completed by the subject 4 months after initiating Side1 treatment. 12.2. Descriptive statistics of satisfaction questionnaire and aesthetic result perception, completed by the subject 6 months after initiating Side1 treatment. 12.3. Descriptive statistics of satisfaction questionnaire and aesthetic result perception, completed by the subject 12 months after initiating Side1 treatment. 12.4. Descriptive statistics of satisfaction questionnaire and aesthetic result perception, completed by the subject 6 months after initiating Side2 treatment. 12.5. Descriptive statistics of satisfaction questionnaire and aesthetic result perception, completed by the subject 8 months after initiating Side2 treatment. |
4, 6 and 12 months after initiating Side 1 treatment, as well as 6 and 8 months after initiating Side2 treatment
|
Incidence, seriousness, severity and relationship of adverse events with the treatment with Sculptra
Time Frame: An average of 1 year
|
13.1. Incidence, seriousness, severity and relationship with management of adverse events reported during study period. 13.2. Incidence, seriousness, severity and relationship with management of adverse events of interest reported during study period. 13.3. Incidence of treatment discontinuations due to adverse events reported during study period |
An average of 1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Samira Yarak, Federal University of São Paulo
- Principal Investigator: Marisa G Cunha, Fundacao do ABC
- Principal Investigator: Doris M Hexsel, Centro Brasileiro de Estudos em Dermatologia
- Principal Investigator: Alessandra Haddad, Hospital Israelita Albert Einstein
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BR.16.001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Flaccidity, Muscle
-
Derming SRLCompletedSkin Flaccidity Inner Thighs Knees ArmsItaly
-
Derming SRLCompletedSkin Flaccidity and Roughness of the Abdomen and Inner ArmsItaly
-
United States Army Research Institute of Environmental...US Army Natick Soldier Research, Development & Engineering CenterCompletedMuscle Loss | Muscle Anabolism | Muscle PerformanceUnited States
-
University Hospital, Strasbourg, FranceTerminated
-
Christian Müller, MDUniversity Hospital Inselspital, Berne; Medical University Innsbruck; University... and other collaboratorsRecruitingMuscle Weakness | Muscle Atrophy | Muscle Spasticity | Muscle Cramp | Muscle Soreness | Muscle Damage | Myopathy | Muscle InjurySwitzerland, Austria
-
United States Army Research Institute of Environmental...Tufts UniversityCompletedMuscle Loss | Muscle AnabolismUnited States
-
Çağtay MadenCompletedForward Head Posture | Muscle Tone | Muscle Stiffnes | Muscle Elasticty | Vital CapacityTurkey
-
Koç UniversityCompletedMuscle Strength | Posture | Abdominal MuscleTurkey
-
University of Texas Southwestern Medical CenterAbhimanyu Garg; Prishant Mishra; Jimin RenCompletedMuscle Weakness | Muscle Cramp | Muscle Stiffness | Statin-related Muscle Pain | Muscle AchesUnited States
-
University of LiegeRecruitingMuscle Strength | Shoulder | Electromyography | Muscle ActivationBelgium
Clinical Trials on Poly-L-lactic acid - Sculptra
-
Galderma R&DCompletedWrinkles in DecolletageUnited States
-
Bausch Health Americas, Inc.Completed
-
Bausch Health Americas, Inc.CompletedFacial LipoatrophyUnited States
-
Erevna Innovations Inc.Completed
-
Bausch Health Americas, Inc.Completed
-
Bausch Health Americas, Inc.CompletedMid Facial Contour DeficienciesUnited Kingdom
-
Williams Center Plastic Surgery SpecialistsSanofiCompleted
-
Taipei Medical University HospitalTaipei Medical University; Panion & BF Biotech Inc.RecruitingNasolabial Fold WrinklesTaiwan
-
Henry Ford Health SystemGalderma R&DCompletedStriae DistensaeUnited States